Screening for hemochromatosis

Clinica Chimica Acta

Volumn 315, Issue 1-2, 2002, Pages 169-186

  McCullen, Mark A ^a   Crawford, Darrell H G ^a   Hickman, Peter E ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Hemochromatosis; HFE genotyping; Screening; Total iron binding capacity; Transferrin saturation; Unsaturated iron binding capacity

Indexed keywords

FERRITIN; IRON; TRANSFERRIN;

COMMUNITY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; ETHICS; FERRITIN BLOOD LEVEL; GENOTYPE; HEMOCHROMATOSIS; HUMAN; INFORMED CONSENT; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON DEFICIENCY; LABORATORY DIAGNOSIS; LEGAL ASPECT; LIVER BIOPSY; MASS SCREENING; PENETRANCE; PHENOTYPE; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SOCIAL ASPECT; WORLD HEALTH ORGANIZATION;

ADULT; ALGORITHMS; BIOPSY; COST-BENEFIT ANALYSIS; FEMALE; FERRITINS; FORECASTING; GENETIC SCREENING; GENOTYPE; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; INFORMED CONSENT; INTESTINAL ABSORPTION; IRON; LIVER CIRRHOSIS; MALE; MASS SCREENING; MEMBRANE PROTEINS; TRANSFERRIN;

EID: 0036133173     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00711-2     Document Type: Review

References (92)

1. Management of hemochromatosis
2. Hemochromatosis and other iron storage diseases
3. A novel MHC class-I like gene is mutated in patients with hereditary hemochromatosis
4. Population screening for hemochromatosis
5. Hereditary hemochromatosis. Gene discovery and its implications for population-based screening
6. Hemochromatosis and dietary iron supplementation: Implications from US mortality, morbidity and health survey data
7. Hemochromatosis-associated mortality in the United States from 1979 to 1992: An analysis of multiple-cause mortality data
8. Diagnosis of hemochromatosis
9. Long-term survival in patients with hereditary hemochromatosis
10. Survival and causes of death in cirrhotic and noncirrhotic patients with primary hemochromatosis
11. Hemochromatosis: Precirrhotic therapy restores normal life expectancy
12. Long-term survival analysis in hereditary hemochromatosis
13. Portal hypertension and iron depletion in patients with genetic hemochromatosis
14. Principles and practice of screening for disease
15. Research priorities in hereditary hemochromatosis
16. Screening for hemochromatosis: A public health perspective
17. Hereditary hemochromatosis: To screen or not. Conditions for screening are not yet fulfilled
18. Screening for hemochromatosis in primary care settings
19. EASL International Consensus Conference on Hemochromatosis
20. Inherited HFE-unrelated hemochromatosis in Italian families
21. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene
22. Two novel nonsense mutations of HFE gene in five unrelated patients with hemochromatosis
23. The gene TRF2 is mutated in a new type of hemochromatosis mapping to 7q22
24. Screening for hemochromatosis: A cost-effectiveness study based on 12,258 patients
25. Practice guideline development task force of the College of American Pathologists, Hereditary Hemochromatosis
26. Screening for hemochromatosis
27. Screening for hemochromatosis
28. Why there is discordance in reported decision thresholds for transferrin saturation when screening for hemochromatosis
29. The relation between chemically measured total iron-binding capacity concentrations and immunologically measured transferrin concentrations in human serum
30. Distribution of transferrin saturation in an Australian population: Relevance to the early diagnosis of hemochromatosis
31. Prevalence of hemochromatosis amongst asymptomatic Australians
32. A population-based study of the clinical expression of the hemochromatosis gene
33. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors
34. Iron overload, public health, and genetics: Evaluating the evidence of hemochromatosis screening
35. Twenty-four hour variation of transferrin saturation in treated and untreated hemochromatosis homozygotes
36. Prevalence of hemochromatosis in a sample of 16,031 primary care patients
37. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of hemochromatosis
38. A screening test for assessing iron status
39. Screening test for iron overload
40. Population screening for hemochromatosis: A comparison of unbound iron binding capacity, transferrin saturation and C282Y genotyping in 5,211 voluntary blood donors
41. Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous hemochromatosis
42. Population screening for hemochromatosis: A unified analysis of published intervention trials
43. Neonatal screening for hemochromatosis
44. A retrospective anonymous pilot study in screening newborns for HFE mutations in a Scandinavian population
45. Preliminary studies before systematic screening of hemochromatosis: Prevalence and penetrance of C282Y homozygosity
46. Screening for hereditary hemochromatosis should be implemented now
47. Iron overload in Africa. Interaction between a gene and dietary iron content
48. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in hemochromatosis
49. Polymorphism in intron 4 of HFE does not compromise hemochromatosis mutation results
50. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation
51. Caught in the middle again: Professional ethical considerations in genetic testing for health risks
52. ASHG/ACMG report: Points to consider: Ethical, legal, and psychosocial implications of genetic testing in children and adolescents
53. Molecular medicine and hemochromatosis: At the crossroads
54. Phenotypic expression of HFE mutations: A French study of 1110 unrelated iron-overloaded patients and relatives
55. HFE mutations analysis in 711 hemochromatosis probands: Evidence for S65C implication in mild forms of hemochromatosis
56. Prevalence of hereditary hemochromatosis in a Massachusetts corporation: Is Celtic origin a risk factor?
57. The significance of hemochromatosis gene mutations in the general population: Implications for screening
58. Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri
59. The effect of HFE genotypes on the measurements of iron overload in patients attending a health appraisal clinic
60. Incidence of liver disease in people with HFE mutations
61. HFE (hemochromatosis gene) C282Y homozygotes in an elderly male population
62. Concordance of iron storage in siblings with genetic hemochromatosis: Evidence for a predominantly genetic effect on iron storage
63. Evidence that the ancestral haplotype in Australian hemochromatosis patients may be associated with a common mutation in the gene
64. Concordance of iron indices between family members within hemochromatosis families: Further evidence that additional modifying genes influence HFE gene expression in hemochromatosis
65. Of metals, mice and men: What animal models can teach us about body iron loading
66. Factors affecting the concentrations of ferritin in serum in a healthy Australian population
67. Hepatic cirrhosis in hereditary hemochromatosis is seldom due solely to iron: Evidence for a synergistic effect of alcohol and iron
68. Clinical course of non-expressing homozygotes for hemochromatosis
69. Screening blood donors for hereditary hemochromatosis: Decision analysis model comparing genotyping to phenotyping
70. Large-scale screening for HFE mutations: Methodology and cost
71. Five hundred life-saving interventions and their cost-effectiveness
72. Population screening for hemochromatosis
73. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age
74. Should all people over the age of 50 have regular fecal occult-blood tests?
75. Role of family history and family testing in cardiovascular risk assessment
76. Laws restricting health insurer's use of genetic information: Impact on genetic discrimination
77. Psychosocial impact of genetic screening for hemochromatosis in population screening and referred patients
78. Non-invasive prediction of fibrosis in C282Y homozygous hemochromatosis
79. HFE genotype in patients with hemochromatosis and other liver diseases
80. Population screening for hemochromatosis: Expectations based on a study of relatives of symptomatic probands
81. Disease-related conditions in relatives of patients with hemochromatosis
82. Hemochromatosis in the new millennium
83. Natural history and development of symptoms after iron depletion in C282Y hemochromatosis
84. The effect of HFE mutations on serum ferritin and transferrin saturation in the Jersey population
85. Screening for hereditary hemochromatosis in siblings and children of affected patients
86. Screening for hemochromatosis in children of homozygotes: Prevalence and cost-effectiveness
87. Hereditary hemochromatosis: Presentation and diagnosis in the 1990s
88. Clinical presentation of hemochromatosis: A changing scene
89. Hereditary hemochromatosis should be more widely known about